Home > Team
The management team of the Erasmus MC Biomedical Fund has a successful track record in sourcing, structuring and exiting seed and spin-out companies. Such experience and track-record allows the fund to provide the required hands-on operational assistance to the fund's portfolio companies.
Tom Schwarz, partner, possesses seed and early stage investment and corporate experience. Tom co-founded the Erasmus MC Biomedical Fund in 2007. In 2009 he founded a similar university venture capital fund in Amsterdam, the Life Sciences Fund Amsterdam. Tom started his venture capital career in 1998, when he co-founded Life Sciences Partners (LSP), a leading European life sciences venture capital fund with offices in Amsterdam, Munich and Boston. Tom enjoys strong contacts within the academic and pharmaceutical community. Tom, a pharmacist by training, gained his experience in the life sciences industry as a CEO of U-Gene Research, a contract research organization in the Netherlands, which he sold in 1997 to Kendle (US). Tom has led a number of investment processes, including Sequenom, Introgene, Semaia, Santarus, Skyline, River Diagnostics, ArGENX and AIMM Therapeutics and has held board positions at most of these companies. Four of the investments that Tom has played a role in have gone public, i.e. Crucell, Santarus, Sequenom and DeVGen. Furthermore, Tom has extensive experiences with start-up companies, e.g. he was actively involved in founding and management of several biotech start-ups, involving strategy development, fundraising, and analyzing M&A opportunities; and in the sourcing and initialization of university spin-outs.
Tel: + 31 653279243
Harm de Vries, partner, has extensive experience in structuring, establishing and monitoring venture capital transactions and university spin-outs and in setting-up and operating (university) venture funds. In 2007 and 2009, Harm has co-founded the university funds Erasmus MC Biomedical Fund and the Life Sciences Fund Amsterdam, which he co-manages with Tom Schwarz. Harm holds board positions at Cavadis and Therosteon. Before Harm started the Erasmus MC Biomedical Fund he worked as General Counsel at LSP, where he was responsible for all legal issues connected with the investments and divestments (M&A, IPO) of the portfolio companies, including legal due diligence, drafting of term sheets and contracts, and review of intellectual property. Harm started his career as an attorney at law at an Amsterdam-based law firm. Harm has acted as speaker at many venture capital related symposia and was amongst others speaker at EVCA Venture Capital Courses for Investment Professionals. In 2005, Harm authored the guide book: “Venture Capital Term Sheets, a guide to structuring and negotiating venture capital term sheets” (Reed Elsevier).
Tel: + 31 653216339